

News Release

STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

Record first-half revenue for Fisher & Paykel Healthcare; net profit up 43%

Auckland, New Zealand, 28 November 2024 – Fisher & Paykel Healthcare Corporation Limited (NZX:FPH, ASX:FPH) today announced its results for the first half of the 2025 financial year, which ended 30 September 2024.

Total operating revenue was a record \$951.2 million, an increase of 18% from the prior corresponding period or 17% in constant currency. Net profit after tax for the first half was \$153.2 million, up 43% over the same period in the previous financial year, or 51% in constant currency.

“This result was driven primarily by new product introductions and changing clinical practice. Early indications are that a relatively high hospital census during the period may have contributed as well, as hospitals returned to more normalised staffing and capacity, and seasonal hospitalisations in the Northern Hemisphere from FY24 persisted into the beginning of our current financial year,” said Managing Director and Chief Executive Officer Lewis Gradon.

For the Hospital product group, which includes humidification products used in respiratory, acute and surgical care, first-half revenue was \$591.4 million, an increase of 21% over the same period last year in both reported and constant currency. Hospital new applications consumables revenue increased 24% in constant currency.

For the Homecare product group, first-half revenue was a record \$359.4 million, an increase of 14% on the first half of last year, or 13% in constant currency. Sales of masks and accessories for treating obstructive sleep apnea (OSA) were up 14% in constant currency.

“Growth has been broad-based across our entire portfolio of hospital products, including in invasive and noninvasive ventilation and Optiflow for respiratory and anesthesia patients, all suggesting that we are making headway with changing clinical practice.

“We are also pleased with the continued strong performance of our range of masks for patients with obstructive sleep apnea. With the introduction of the F&P Nova Micro mask, alongside our recently launched F&P Solo AutoFit mask and F&P Evora Full, we address a diverse array of patient needs and preferences with our latest technology,” said Mr Gradon.

Gross margin was 61.9% for the first half of the 2025 financial year, which was a 141 basis-point increase in reported currency over the prior comparable period, or a 198 basis-point increase in constant currency.

The company’s directors have approved an interim dividend of 18.5 cents per ordinary share, up from 18 cents per share in the first half of the prior year. The interim dividend, carrying full New Zealand imputation credit, will be paid on 18 December 2024 with a record date of 6 December 2024.

Given the company’s strong financial performance and reduction of debt, the Board has determined to suspend the dividend reinvestment plan (DRP). As a result, shareholders who have previously elected to participate in the DRP will receive their dividends for this period in cash.

Looking ahead

The full-year guidance previously provided in August was for operating revenue to be in the range of approximately \$1.9 billion to \$2.0 billion and net profit after tax to be in the range of approximately \$320 million to \$370 million.

At 31 October exchange rates*, the company continues to guide to full-year operating revenue in the range of approximately \$1.9 billion to \$2.0 billion and full-year net profit after tax in the range of approximately \$320 million to \$370 million.

“In our Homecare product group, we have introduced three new mask models into major markets over the last ten months. They are performing well, and we think they will continue to drive similar results for the remainder of the financial year,” said Mr Gradon.

“For our Hospital product group, we expect similar contributions from change in clinical practice and new product introductions. Our revenue guidance range also accommodates a broad range of Northern Hemisphere seasonal hospitalisation scenarios, ranging from relatively low to approximately moderate. This variable impact typically occurs later in our second half.

“We are pleased with our performance for the first half of the year. We want to thank our customers, suppliers, clinical partners, employees and shareholders. Their support makes a difference in the quality of life for millions of patients every year,” concluded Mr Gradon.

*At 31 October 2024 exchange rates of NZD:USD 0.59, NZD:EUR 0.55, NZD:MXN 12.05.

Overview of key results for the first half of the 2025 financial year

- 18% increase in operating revenue to \$951.2 million, 17% increase in constant currency.
- 43% increase in net profit after tax to \$153.2 million, 51% increase in constant currency.
- 21% increase in Hospital operating revenue to \$591.4 million, 21% increase in constant currency.
- 24% increase in constant currency for new applications consumables (products used in noninvasive ventilation, Optiflow nasal high flow and surgical applications) accounting for 73% of Hospital consumables revenue.
- 14% increase in Homecare operating revenue to \$359.4 million, 13% increase in constant currency.
- 14% increase in constant currency for OSA masks and accessories revenue.
- Investment in R&D was 12% of revenue, or \$110.1 million.
- 3% increase in interim dividend to 18.5 cps (H1 FY24: 18 cps).

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. Our products are sold in more than 120 countries worldwide. For more information, visit our website www.fphcare.com.

Contacts

Media

Karen Knott
GM Corporate Communications
karen.knott@fphcare.co.nz
+64 (0) 21 713 911

Investors

Dan Adolph
Head of Investor Relations
daniel.adolph@fphcare.co.nz
+64 (0) 22 511 4050

Authorised by Fisher & Paykel Healthcare Corporation Limited's Board of Directors.

Accompanying documents

Attached to this news release are the following additional documents:

- Results in Brief
- Interim Report 2025
- Investor Presentation
- NZX Results Announcement
- NZX Distribution Notice

Constant currency information

Constant currency information included within this news release is non-GAAP financial information, as defined by the NZ Financial Markets Authority, and has been provided to assist users of financial information to better understand and track the company's comparative financial performance without the impacts of spot foreign currency fluctuations and hedging results and has been prepared on a consistent basis each year. A constant currency analysis is included on page 12 of the company's

Interim Report 2025, and the company's constant currency framework can be found on the company's website at www.fphcare.com/ccf.

Half year results conference call

Fisher & Paykel Healthcare will host a conference call on Thursday, 28 November 2024 to discuss the half year result. The conference call is scheduled to begin at 10:00am NZDT, 8:00am AEDT (4:00pm USEST, Wednesday 27 November) and will be simultaneously broadcast online.

To listen to the webcast, access the company's website at www.fphcare.com/investor. An online archive of the event will be available approximately two hours after the webcast and will remain on the site for two weeks.

To listen and participate in the conference call via phone, please register via 'GlobalMeet' by clicking this [link](#). Once registered, click 'Call Me' and you will receive a phone call connecting you through to the conference line.

Results in Brief

	Six Months Ended 30 Sep 23 NZ\$M (except as otherwise stated)	Six Months Ended 30 Sep 24 NZ\$M (except as otherwise stated)	% Change (Reported)	% Change (Constant Currency ¹)
FINANCIAL PERFORMANCE				
Total operating revenue	803.7	951.2	+18%	+17%
Cost of sales	(317.6)	(362.5)	+14%	+12%
Gross profit	486.1	588.7	+21%	+21%
Gross margin	60.5%	61.9%	+141 bps	+198 bps
Selling, general and administrative expenses	(236.6)	(260.5)	+10%	+10%
Research and development expenses	(96.9)	(110.1)	+14%	+14%
R&D percentage of operating revenue	12.1%	11.6%	-48 bps	-39 bps
Total operating expenses	(333.5)	(370.6)	+11%	+11%
Operating profit before financing costs	152.6	218.1	+43%	+46%
Operating margin	19.0%	22.9%	+394 bps	+420 bps
Net financing expense	(12.0)	(11.7)	-3%	-58%
Profit before tax	140.6	206.4	+47%	+52%
Tax expense	(33.3)	(53.2)	+60%	+58%
Profit after tax	107.3	153.2	+43%	+51%
Effective tax rate	23.7%	25.8%		
Effective tax rate excluding R&D tax credit	29.9%	30.1%		

Revenue by Region:

North America	366.2	444.9	+21%
Europe	207.5	248.8	+20%
Asia Pacific	179.8	205.1	+14%
Other	50.2	52.4	+4%
Total	803.7	951.2	+18%

Revenue by Product Group:

Hospital	487.5	591.4	+21%
Homecare	314.4	359.4	+14%
Core products sub-total	801.9	950.8	+19%
Distributed and other	1.8	0.4	-78%
Total	803.7	951.2	+18%

	As at 31 Mar 24 NZ\$M (except as otherwise stated)	As at 30 Sep 24 NZ\$M (except as otherwise stated)	
FINANCIAL POSITION			
Tangible assets	2,100.8	2,259.4	+8%
Intangible assets ²	180.9	176.0	-3%
Total assets	2,281.7	2,435.4	+7%
Total liabilities	(522.6)	(505.6)	-3%
Shareholders' equity	1,759.1	1,929.8	+10%
Gearing	1.8%	-2.9%	-256%
Net tangible asset backing (cents per share)	271	305	+13%

¹ Constant currency (CC) removes the impact of exchange rate movements. This approach is used to assess the Group's underlying comparative financial performance without any impact from changes in foreign exchange rates. The company's constant currency framework can be found on the company's website at www.fphcare.com/ccf. The reconciliation to reported results is included within the Financial Commentary section of the Interim Report.

² Includes Intangible and deferred tax assets.

Results in Brief (continued)

	Six Months Ended 30 Sep 23 NZ\$M (except as otherwise stated)	Six Months Ended 30 Sep 24 NZ\$M (except as otherwise stated)	% Change
CASH FLOWS			
Net cash flow from operating activities	156.5	233.0	+49%
Net cash flow from investing activities	(275.5)	(55.1)	-80%
Net cash flow from financing activities	66.0	(137.2)	-308%
SHARES OUTSTANDING			
Weighted average basic shares outstanding	580,581,693	584,954,554	
Weighted average diluted shares outstanding	584,542,333	589,385,621	
Basic shares outstanding at period end	582,012,620	586,112,745	
DIVIDENDS AND EARNINGS PER SHARE			
Dividends per share (cents) – declared	18.0	18.5	+3%
Basic earnings per share (cents)	18.5	26.2	+42%



Contents

Welcome to our 2025 Interim Report. In this, we highlight the performance and financial results of Fisher & Paykel Healthcare for the six months ended 30 September 2024.

Half year financial highlights	2
Business highlights	3
Product group overview	4
Half year review	6
Financial commentary	9
Financial statements	13
Notes to the financial statements	17
Independent auditor's review report	20
Directory	21

Constant currency information contained within this report is non-conforming financial information, as defined by the New Zealand Financial Markets Authority and has been provided to assist users of financial information to better understand and assess the company's financial performance without the impacts of spot financial currency fluctuations and hedging results, and has been prepared on a consistent basis each financial year. A reconciliation between reported results and constant currency results is available on page 12 of this report. The company's constant currency framework can be found on our website at www.fphcare.com/ccf.

This report is dated 27 November 2024 and is signed on behalf of Fisher & Paykel Healthcare Corporation Limited by Neville Mitchell, Board Chair and Lewis Gradon, Managing Director and Chief Executive Officer. A digital version of this report is available at www.fphcare.com/nz/corporate/investor/reports/.



NEVILLE MITCHELL
BOARD CHAIR



LEWIS GRADON
MANAGING DIRECTOR AND
CHIEF EXECUTIVE OFFICER

Half year financial highlights

OPERATING REVENUE
\$951.2 MILLION

↑ **18%**

NET PROFIT AFTER TAX
\$153.2 MILLION

↑ **43%**

GROSS MARGIN

61.9%

▲ 198 BPS (CONSTANT CURRENCY)

INTERIM DIVIDEND
FULLY IMPUTED

18.5CPS

▲ 3% | 18.0CPS (1H FY24)

HOSPITAL REVENUE
\$591.4 MILLION

↑ **21%**

HOMECARE REVENUE
\$359.4 MILLION

↑ **14%**

REVENUE BY REGION


6 MONTHS TO 30 SEPTEMBER 2024



● North America ● Other
● Europe
● Asia Pacific

REVENUE BY PRODUCT GROUP

6 MONTHS TO 30 SEPTEMBER 2024



● Hospital
● Homecare
● Distributed & Other

Half year business highlights



RELEASED

two new hardware platforms into the United States: the F&P 950™ System and Airvo™ 3



INITIATED

sales of our new F&P Optiflow Duet™ in the United States



LAUNCHED

our F&P Nova Micro™ nasal pillows mask for treating obstructive sleep apnea in New Zealand and Canada



COMMENCED

sales of our F&P Solo™ nasal and pillows mask in the United States



BEGAN

manufacturing at our new facility in Guangzhou, China



APPOINTED

Mark Cross to the Board of Directors, and welcomed Neville Mitchell to the role of Board Chair

PRODUCT GROUP OVERVIEW

Our business is structured in two parts: Hospital and Homecare.

Hospital

Our Hospital product group includes products used in invasive ventilation, noninvasive ventilation, high flow therapy, anesthesia, and laparoscopic and open surgery. Not only do these products help healthcare providers improve patient outcomes, they often deliver economic benefits as well, by reducing the need to escalate care and shortening patient stays in hospital.

FEATURED PRODUCT



62%

OF OPERATING REVENUE

OPERATING REVENUE
\$591.4 MILLION

↑21%

CONSTANT CURRENCY REVENUE FROM
NEW APPLICATIONS CONSUMABLES

↑24%

Homecare

Our Homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home. These include our CPAP therapy masks as well as flow generators, interfaces and data management technologies.

FEATURED PRODUCT



38%

OF OPERATING REVENUE

OPERATING REVENUE
\$359.4 MILLION

↑ **14%**

CONSTANT CURRENCY REVENUE
FROM OSA MASKS AND ACCESSORIES

↑ **14%**

Half year review



NEVILLE MITCHELL
Board Chair

Within our business we often talk about ‘fundamentals’. These are the guiding principles that underpin the way we work, collaborate and make decisions, and ultimately, help us fulfil our purpose of improving care and outcomes.

Our strategy for achieving sustainable, profitable growth comes down to three fundamentals – creating world-leading products, increasing our global presence, and working with healthcare providers to transform clinical practice. Those fundamentals have proven successful, and they drove another strong result for the first half of the 2025 financial year.

For the six months ended 30 September 2024, total operating revenue was a record \$951.2 million, an increase of 18% above the first half of the 2024 financial year, or 17% in constant currency. Net profit after tax was \$153.2 million, 43% above the same period last year, or 51% in constant currency. These results were driven primarily by changing clinical practice and launching new products in our largest markets.

Early indications are that a relatively high hospital census may have contributed as well, as elevated seasonal hospitalisations in the United States persisted into the beginning of our current financial year.

For the Hospital product group, first-half revenue was \$591.4 million, an increase of 21% over the same period last year and 21% in constant currency. For the Homecare product group, first-half revenue was a record

\$359.4 million, an increase of 14% on the first half of last year, or 13% in constant currency. Sales of masks and accessories were up 14% in constant currency.

As we have said before, our goal is to return to our gross margin target of 65% while maintaining our growth aspirations. During the first half of 2025, gross margin was 61.9%, which was a 198 basis-point increase in constant currency from the first half of the prior financial year. Improving gross margin remains a priority for the business, and we will be aiming to grow expenses over the next few years at a level below revenue growth.

PRODUCT UPDATE

Our investment in research and development continues to yield positive results, and we reached a number of milestones across both product groups during the first half of the year.

In our Hospital business, we launched the F&P 950™ humidification system in the United States, as well as the F&P Optiflow Duet™ interface, a consumable nasal cannula for respiratory support. We also received clearance from the US Food and Drug Administration for F&P Optiflow Switch™, a product used in anaesthesia.

In Homecare, our portfolio of products for treating obstructive sleep apnea was strengthened recently with the addition of two new masks. In April, the F&P Solo™ was released in the United States, and it has received great reviews from patients. A few weeks ago, F&P Nova Micro™ was launched in the United States, and we look forward to seeing how the mask performs in that market.

Our strategy for achieving sustainable, profitable growth comes down to three fundamentals – creating world-leading products, increasing our global presence, and working with healthcare providers to transform clinical practice.

INFRASTRUCTURE

Establishing a third manufacturing location has been a priority for the past several years. In July we received final regulatory clearance for our facility in Guangzhou, China. The site is now fully operational, and we have now begun selling products manufactured at this facility.

We have previously announced the purchase of land in Karaka, Auckland, for a second New Zealand campus, and we recently submitted the formal rezoning application. Although construction is still years away, plans are in development, and we are working with mana whenua to enhance the site. Recently, more than 60 of our employees and their families volunteered to plant 1,000 trees to protect the site's waterways.

YOUR BOARD

Our previous Board Chair, Scott St John, retired following the 2024 Annual Shareholders' Meeting after nine years as a director. Scott led the Board during the challenging years of the pandemic and an exciting time of growth for the business. On behalf of the entire Board, we want to acknowledge Scott's tenure and thank him for his guidance and deep commitment.

In early October we filled the vacancy left by Scott and welcomed Mark Cross as an independent director. Mark is a strategic thinker with strong financial acumen, and the Board will benefit from his breadth of skills and extensive governance experience. Mark has been appointed to chair the Audit and Risk Committee.

DIVIDEND

The Board of Directors has approved an interim dividend of 18.5 cents per share for the six months to 30 September 2024, an increase of 3% from the first half of the prior year. This will be paid on 18 December 2024 with a record date of 6 December 2024.

Given the company's strong performance over the last few years and reduction of debt so that net cash is now within the target gearing range, the Board has determined to suspend the dividend reinvestment plan (DRP). As a result, shareholders who have previously elected to participate in the DRP will receive their dividends for this period in cash.

ACKNOWLEDGEMENTS

We are pleased with our performance in the first half of the year, and it is our practice to reward our people for their contribution to our success. With that in mind, the Board has approved a profit-sharing payment totalling \$6 million to be shared among employees who have worked for the company for a qualifying period.

Once again, we want to thank our customers, suppliers, clinical partners and shareholders for your support. Your trust in Fisher & Paykel Healthcare – and our 'fundamentals' – makes a difference in the quality of life for millions of patients every year.



NEVILLE MITCHELL
Board Chair



LEWIS GRADON
Managing Director and
Chief Executive Officer

Financial report



Financial commentary

INCOME STATEMENTS

For the six months ended 30 September	2023 NZ\$M	2024 NZ\$M	Change Reported %	Change CC ¹ %
Operating revenue	803.7	951.2	+18	+17
Gross profit	486.1	588.7	+21	+21
Gross margin	60.5%	61.9%	+141 bps	+198 bps
SG&A expenses	(236.6)	(260.5)	+10	+10
R&D expenses	(96.9)	(110.1)	+14	+14
Total operating expenses	(333.5)	(370.6)	+11	+11
Operating profit	152.6	218.1	+43	+46
Operating margin	19.0%	22.9%	+394 bps	+420 bps
Net financing (expense)	(12.0)	(11.7)	-3	-58
Profit before tax	140.6	206.4	+47	+52
Tax expense	(33.3)	(53.2)	+60	+58
Profit after tax	107.3	153.2	+43	+51

¹ Constant currency (CC) removes the impact of exchange rate movements. This approach is used to assess the Group's underlying comparative financial performance without any impact from changes in foreign exchange rates. See further details on page 12.

Total profit after tax for the period was \$153.2 million, a 43% increase from the same period last year, or 51% in constant currency.

Revenue

Operating revenue was \$951.2 million, an 18% increase from the prior comparable period (PCP) or 17% in constant currency. Revenue was strong across all products and regions. Hospital revenue grew 21% in constant currency, reflecting continued clinical change and a good response to new product introductions and high hospital census. Homecare revenue grew 13% in constant currency with strong growth in masks and accessories of 14% in constant currency.

Gross margin

Gross margin at 61.9% improved by 198 basis points in constant currency from the same period last year. This reflects the continued progress of our improvement initiatives and overhead efficiency.

Operating expenses

Operating expenses increased 11% (11% in constant currency) to \$370.6 million, reflecting our ongoing investment in sales, marketing and R&D to support the development of our product pipeline and our global sales growth.

Financing expenses


During the period, interest expense decreased to \$4.9 million (Sep 2023: \$8.7 million) with lower borrowings, reflecting the strong cash generation over the past year. The net financing expense of \$11.7 million remains largely unchanged from the prior period, with higher net foreign exchange losses of \$8.5 million (Sep 2023: \$4.7 million), offsetting the decreased interest expense.

Tax

Our effective tax rate for the period was 25.8%, up from 23.7% in the prior period. The R&D tax credit for this period of \$9.0 million (Sep 2023: \$8.8 million) represents the tax credit available on the estimated eligible R&D expenditure incurred during the period. Excluding the benefit of the R&D tax credit, the effective tax rate was 30.1% (Sep 2023: 29.9%).

FOREIGN CURRENCY IMPACTS

The Group is exposed to movements in foreign exchange rates, with approximately 99% of operating revenue generated in currencies other than NZD as shown below.



Over 60% of COGS and 50% of operating expenses are in currencies other than NZD.

Foreign currency impacts had a negative effect of \$2.7 million on net profit after tax when compared to the prior period. Net foreign exchange losses on balance sheet translations reduced profit after tax for the period by \$6.8 million (Sep 2023: \$1.6 million decrease). The hedging programme contributed a pre-tax gain in the period of \$12.9 million (Sep 2023: \$2.8 million loss).

The average daily spot rate, the average conversion exchange rate (the accounting rate, incorporating the benefit of forward exchange contracts in respect of the relevant financial year), and the closing spot rate of the main foreign currency exposures for the reported periods are set out in the table to the right.

Six months ended 30 September	Average daily spot rate		Average conversion exchange rate		Closing spot rate	
	2023	2024	2023	2024	31 March 2024	30 September 2024
USD	0.612	0.608	0.666	0.624	0.599	0.637
EUR	0.562	0.559	0.544	0.541	0.554	0.571
MXN	10.63	11.00	13.73	12.32	9.91	12.54

Foreign exchange hedging position

In line with our hedging programme, additional hedges have been added for future years. The hedging position for our main currency exposures as at 13 November 2024 is:

Year to 31 March	FY25	FY26	FY27	FY28	FY29	FY30 - FY35*
USD % cover of expected exposure	95%	80%	70%	50%	20%	0%
USD average rate of cover	0.619	0.608	0.599	0.588	0.566	0.523
EUR % cover of expected exposure	95%	80%	70%	55%	45%	10%
EUR average rate of cover	0.536	0.535	0.529	0.527	0.510	0.474
MXN % cover of expected exposure	85%	60%	40%	15%	5%	0%
MXN average rate of cover	12.67	12.49	12.92	14.07	14.64	15.06

* FY30 - FY35 shows average % cover of expected exposure and rate of cover for the five-year period.

Hedging cover has been rounded to the nearest 5%.

CASH FLOWS

The full statement of cash flows is provided on page 16.

	2023 NZ\$M	2024 NZ\$M	Change NZ\$M
For the six months ended 30 September			
Operating profit before financing costs	152.6	218.1	65.5
Plus depreciation and amortisation	54.4	67.4	13.0
Change in working capital and other	(14.4)	6.9	21.3
Net interest paid	(7.8)	(5.6)	2.2
Net income tax paid	(28.3)	(53.8)	(25.5)
Operating cash flows	156.5	233.0	76.5
Lease repayments	(8.5)	(8.5)	-
Purchase of land and buildings	(224.5)	(15.8)	208.7
Purchase of plant and equipment	(39.4)	(23.8)	15.6
Purchase of intangible assets	(11.6)	(15.5)	(3.9)
Free cash flows*	(127.5)	169.4	296.9
Dividends paid	(81.7)	(87.5)	(5.8)

* Free cash flows include lease liability repayments following the adoption of NZ IFRS 16.

Operating cash flows

Cash flows from operations for the period increased to \$233.0 million (Sep 2023: \$156.5 million). Operating cash flows benefited from the increased net profit and favourable net working capital movements. Tax payments have normalised this year after being lower in the prior period from prepayments in the 2023 financial year.

Capital expenditure

During the period, \$55.1 million was spent on capital expenditure (excluding leased assets), including our East Tāmaki campus development for the car park and earthworks and design for our fifth building.

Dividends

Dividends paid of \$87.5 million increased 7% from the prior period. The Dividend Reinvestment Plan (DRP) continued to be in place for the 2024 final dividend paid during this period. Under the DRP, \$49.7 million of dividends were reinvested as new shares this period, reducing the cash paid by the same amount (2023: \$51.6 million).

BALANCE SHEET

	31 March 2024 NZ\$M	30 September 2024 NZ\$M	Change NZ\$M
As at			
Trade receivables	219.5	212.5	(7.0)
Inventories	320.4	332.7	12.3
Less trade and other payables*	(111.3)	(111.2)	0.1
Working capital	428.6	434.0	5.4
Property, plant and equipment**	1,340.0	1,335.7	(4.3)
Intangible assets	88.4	82.9	(5.5)
Lease liabilities	(74.9)	(84.3)	(9.4)
Other net assets (liabilities)	9.2	111.5	102.3
Net cash (debt)	(32.2)	50.0	82.2
Net assets	1,759.1	1,929.8	170.7

* Trade and other payables exclude all non-current payables and all employee entitlements and provisions.

** Property, plant and equipment includes lease assets recognised.

Trade receivables have decreased at 30 September 2024, primarily reflecting unfavourable exchange rates. Our debtor days were within the normal range at 44 days (Mar 2024: 45 days). Inventories balances have increased, reflecting our usual build as we approach the Northern Hemisphere winter.

Property, plant and equipment (including leased assets) decreased by \$4.3 million in the period including a decrease of \$8.3 million on foreign currency translation and depreciation expense. These have been largely offset by capital additions.

Intangible assets decreased by \$5.5 million, with amortisation more than offsetting total expenditure during the period. The additions include patent and trademarks and ERP system spending with our global SAP rollout continuing over the next year.

Other net assets movements included the movements from derivative financial instruments, provisions and net deferred tax assets.

The derivative financial instruments increased by \$136.2 million from net assets of \$59.0 million at 31 March 2024 to \$195.2 million at 30 September 2024. This is primarily due to the change in exchange rates at 30 September 2024 compared to 31 March 2024, with the corresponding offset in the cash flow hedge reserve. All currency derivatives continued to be effective hedges.

In March 2024, the Group initiated a voluntary limited recall of Airvo 2 and myAirvo 2 devices manufactured before 14 August 2017. During this period, the Group has utilised \$8.0 million of the total provision related to recall costs incurred to date, reducing the recall provision to \$12.0 million (31 March 2024: \$20.0 million).

Net deferred tax assets decreased by \$27.7 million to \$59.2 million in September 2024, mainly due to the increase in derivative instrument valuations.

Net cash and debt facilities

As at	31 March 2024 NZ\$M	30 September 2024 NZ\$M	Change NZ\$M
Loans and borrowings			
– Current	(77.4)	(66.4)	11.0
– Non-current	(35.7)	-	35.7
Bank overdrafts	(1.1)	(0.2)	0.9
Total interest-bearing liabilities*	(114.2)	(66.6)	47.6
Total cash and investments	82.0	116.6	34.6
Net cash (debt)	(32.2)	50.0	82.2
Gearing	1.8%	-2.9%	-4.7%
Undrawn committed debt facilities	544.3	576.4	32.1
Undrawn uncommitted debt and overdraft facilities	82.0	93.2	11.2

* Excluding lease liabilities.

During the period, the Group's borrowing has reduced by \$47.6 million. As at 30 September 2024, the average maturity of loans and borrowings of \$66.4 million was two months. The currency split for loans and borrowings was 95% USD and 5% Australian dollars. Within the next 12 months, facilities of \$123.0 million will expire, of which \$60.0 million expires on 30 September 2025.

Cash and cash equivalents were \$116.6 million at 30 September 2024, an increase of \$34.6 million during the period. This balance, as well as operating cash generated in the second half of the 2025 financial year, is expected to substantially fund the payment of the interim dividend and ongoing capital expenditure.

Gearing¹

At 30 September 2024, the Group had gearing of -2.9%. This was within the target gearing range of -5% to +5%.

¹ Net interest-bearing debt (debt less cash and cash equivalents and short-term investments) to net interest-bearing debt and equity (less hedging reserves). Net interest-bearing debt excludes lease liabilities.

² From 1 April 2024, all foreign exchange gains and losses from the translation of monetary assets and liabilities are presented within Net financing income / (expense).

NOTES – CONSTANT CURRENCY

Constant currency analysis is non-Generally Accepted Accounting Practice (GAAP) financial information, that is not prepared in accordance with New Zealand Equivalents to International Financial Reporting Standards (NZ IFRS). Constant currency information has been provided to assist users of financial information to better understand and assess the Group's financial performance without the impacts of foreign currency fluctuations, including hedging results.

Constant currency financial information is prepared each month to enable the Board and management to monitor and assess the Group's underlying comparative financial performance without any distortion from changes in foreign exchange rates. Constant currency information is prepared on a consistent basis for reported periods restated into NZD based on "constant" exchange rates, typically the budgeted exchange rates for the current year. This information excludes the impact of movements in foreign exchange rates, hedging results and balance sheet translations.

The Group's constant currency framework can be found on the company's website at www.fphcare.com/ccf. PwC performs certain assurance procedures over the constant currency information.

RECONCILIATION OF CONSTANT CURRENCY TO REPORTED PROFIT AFTER TAX

For the six months ended 30 September	2023 NZ\$M	2024 NZ\$M	Change NZ\$M
Profit after tax (constant currency)	96.1	144.7	48.6
Spot exchange rate effect	14.8	6.0	(8.8)
Foreign exchange hedging result	(2.0)	9.3	11.3
Balance sheet revaluation	(1.6)	(6.8)	(5.2)
Total impact of foreign exchange	11.2	8.5	(2.7)
Profit after tax (reported)	107.3	153.2	45.9

RECONCILIATION OF CONSTANT CURRENCY TO REPORTED REVENUE

For the six months ended 30 September	2023 NZ\$M	2024 NZ\$M	Change NZ\$M
Operating revenue (constant currency)	783.8	919.5	135.7
Spot exchange rate effect	28.1	24.7	(3.4)
Foreign exchange hedging result	(12.1)	7.0	19.1
Balance sheet revaluation ²	3.9	-	(3.9)
Total impact of foreign exchange	19.9	31.7	11.8
Operating revenue (reported)	803.7	951.2	147.5

The significant exchange rates used in the constant currency analysis, being the budget exchange rates for the year ended 31 March 2025, are USD 0.64, EUR 0.57, and MXN 11.0.

Financial statements

CONSOLIDATED INCOME STATEMENT

For the six months ended 30 September 2024

	Notes	Unaudited 2023 NZ\$M	Unaudited 2024 NZ\$M
Operating revenue	3	803.7	951.2
Cost of sales		(317.6)	(362.5)
Gross profit		486.1	588.7
Selling, general and administrative expenses		(236.6)	(260.5)
Research and development expenses		(96.9)	(110.1)
Total operating expenses		(333.5)	(370.6)
Operating profit		152.6	218.1
Financing income		1.4	1.7
Financing expense		(8.7)	(4.9)
Exchange (loss) on translation of foreign currency assets and liabilities		(4.7)	(8.5)
Net financing income / (expense)		(12.0)	(11.7)
Profit before tax	4	140.6	206.4
Tax expense		(33.3)	(53.2)
Profit after tax		107.3	153.2
Basic earnings per share		18.5 cps	26.2 cps
Diluted earnings per share		18.4 cps	26.0 cps

The accompanying notes form an integral part of the financial statements.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 September 2024

	Unaudited 2023 NZ\$M	Unaudited 2024 NZ\$M
Profit after tax	107.3	153.2
Other comprehensive income		
<i>Items that may be reclassified to profit or loss</i>		
Foreign currency translation reserve		
Exchange differences on translation of foreign operations	1.8	(3.0)
Hedging reserves		
Changes in fair value in hedging reserves	(46.9)	147.2
Transfers to profit before tax from cash flow hedge reserve	1.7	(12.9)
Tax on above reserve movements	12.7	(37.6)
Other comprehensive income, net of tax	(30.7)	93.7
Total comprehensive income	76.6	246.9

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 September 2024

	Notes	Share capital NZ\$M	Retained earnings NZ\$M	Reserves NZ\$M	Total equity NZ\$M
Balance at 31 March 2023 (audited)		303.7	1,200.5	249.2	1,753.4
Total comprehensive income		-	107.3	(30.7)	76.6
Dividends paid		-	(133.3)	-	(133.3)
Issue of share capital under dividend reinvestment plan		51.6	-	-	51.6
Issue of share capital under employee share plans		4.8	-	-	4.8
Movement in share based payments reserve		-	-	(1.4)	(1.4)
Movement in treasury shares		0.1	-	-	0.1
Balance at 30 September 2023 (unaudited)		360.2	1,174.5	217.1	1,751.8
Balance at 31 March 2024 (audited)		404.0	1,095.0	260.1	1,759.1
Total comprehensive income		-	153.2	93.7	246.9
Dividends paid	9	-	(137.2)	-	(137.2)
Issue of share capital under dividend reinvestment plan		49.7	-	-	49.7
Issue of share capital under employee share plans		10.5	-	-	10.5
Movement in share based payments reserve		-	-	0.8	0.8
Balance at 30 September 2024 (unaudited)		464.2	1,111.0	354.6	1,929.8

The accompanying notes form an integral part of the financial statements.

CONSOLIDATED BALANCE SHEET

As at 30 September 2024

	Notes	Audited 31 March 2024 NZ\$M	Unaudited 30 September 2024 NZ\$M
ASSETS			
Current assets			
Cash and cash equivalents		82.0	116.6
Trade and other receivables		257.2	253.6
Inventories		320.4	332.7
Derivative financial instruments	5	36.3	50.5
Tax receivable		9.0	14.5
Total current assets		704.9	767.9
Non-current assets			
Derivative financial instruments	5	53.5	154.3
Other receivables		2.4	1.5
Property, plant and equipment		1,340.0	1,335.7
Intangible assets		88.4	82.9
Deferred tax assets		92.5	93.1
Total assets		2,281.7	2,435.4
LIABILITIES			
Current liabilities			
Borrowings		78.5	66.6
Lease liabilities		17.7	20.6
Trade and other payables		219.9	228.7
Provisions		31.0	26.7
Tax payable		18.5	25.7
Derivative financial instruments	5	19.4	4.6
Total current liabilities		385.0	372.9

	Notes	Audited 31 March 2024 NZ\$M	Unaudited 30 September 2024 NZ\$M
LIABILITIES			
Non-current liabilities			
Borrowings		35.7	-
Lease liabilities		57.2	63.7
Provisions		6.3	7.7
Other payables		21.4	22.4
Derivative financial instruments	5	11.4	5.0
Deferred tax liabilities		5.6	33.9
Total liabilities		522.6	505.6
EQUITY			
Share capital		404.0	464.2
Retained earnings		1,095.0	1,111.0
Reserves		260.1	354.6
Total equity		1,759.1	1,929.8
Total liabilities and equity		2,281.7	2,435.4

The accompanying notes form an integral part of the financial statements.

On behalf of the Board
27 November 2024



Neville Mitchell
Board Chair



Lewis Gradon
Managing Director and Chief Executive Officer

CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 September 2024

	Unaudited 2023 NZ\$M	Unaudited 2024 NZ\$M
CASH FLOWS FROM OPERATING ACTIVITIES		
Receipts from customers	797.2	954.8
Interest received	2.3	1.3
Payments to suppliers and employees	(604.6)	(662.4)
Tax paid	(28.3)	(53.8)
Interest paid	(8.7)	(4.7)
Lease interest paid	(1.4)	(2.2)
Net cash flows from operating activities	156.5	233.0
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of property, plant and equipment	(263.9)	(39.6)
Purchases of intangible assets	(11.6)	(15.5)
Net cash flows from investing activities	(275.5)	(55.1)
CASH FLOWS FROM FINANCING ACTIVITIES		
Issue of share capital under employee share plans	1.2	1.5
New borrowings	210.0	40.0
Repayment of borrowings	(55.0)	(82.7)
Lease liability payments	(8.5)	(8.5)
Dividends paid	(81.7)	(87.5)
Net cash flows from financing activities	66.0	(137.2)
Net increase/(decrease) in cash	(53.0)	40.7
Opening cash	116.8	80.8
Effect of foreign exchange rates	0.8	(5.1)
Closing cash	64.6	116.4
RECONCILIATION OF CLOSING CASH		
Cash and cash equivalents	70.5	116.6
Bank overdrafts	(5.9)	(0.2)
Closing cash	64.6	116.4

	Unaudited 2023 NZ\$M	Unaudited 2024 NZ\$M
CASH FLOW RECONCILIATION		
Profit after tax	107.3	153.2
Add (deduct) non-cash items:		
Depreciation – right-of-use assets	8.6	9.8
Depreciation and amortisation – other assets	45.8	57.6
Share based payments	4.5	5.3
Movement in provisions	(4.0)	(2.9)
Movement in deferred tax assets / liabilities	(2.2)	(6.5)
Movement in net tax payables	6.3	3.1
Foreign currency translation	(1.0)	0.8
Other non-cash items	(2.0)	2.9
	56.0	70.1
Net working capital movements:		
Trade and other receivables	(12.7)	4.6
Inventories	5.7	(12.3)
Trade and other payables	0.2	17.4
	(6.8)	9.7
Net cash flows from operating activities	156.5	233.0

The accompanying notes form an integral part of the financial statements.

Notes to the financial statements

For the six months ended 30 September 2024

1. GENERAL INFORMATION

Reporting entity

Fisher & Paykel Healthcare Corporation Limited (the “Company” or “Parent”) together with its subsidiaries (the “Group”) is a leading designer, manufacturer and marketer of medical device products and systems for use in both hospital and homecare settings. Products are sold in over 120 countries worldwide. The Company is a limited liability company incorporated and domiciled in New Zealand. The address of its registered office is 15 Maurice Paykel Place, East Tāmaki, Auckland. These consolidated financial statements were approved for issue by the Board of Directors on 27 November 2024.

Statement of compliance

The Company is registered under the Companies Act 1993 and is an FMC reporting entity under Part 7 of the Financial Markets Conduct Act 2013. The Company is also listed on the New Zealand Stock Exchange (NZX) and the Australian Securities Exchange (ASX).

Basis of preparation

These consolidated financial statements for the six months ended 30 September 2024 have been prepared in accordance with Generally Accepted Accounting Practice in New Zealand (NZ GAAP). They comply with New Zealand Equivalents to International Accounting Standard 34: Interim Financial Reporting (NZ IAS 34) and International Accounting Standard 34: Interim Financial Reporting (IAS 34). The Company and Group are designated as profit-oriented entities for financial reporting purposes.

These consolidated financial statements do not include all of the notes normally included in an annual financial report. Accordingly, this report should be read in conjunction with the audited consolidated financial statements for the year ended 31 March 2024.

Presentation currency

These consolidated financial statements are presented in New Zealand dollars (NZD) to the nearest hundred thousand dollars unless otherwise stated.

Material accounting policies

From 1 April 2024, the Group has changed the accounting presentation of foreign exchange gains and losses from monetary assets and liabilities. These are all now presented within Net financing income / (expense). Other than this presentation change, all material accounting policies have been applied on a basis consistent with those used and described in the audited consolidated financial statements for the year ended 31 March 2024.

2. SIGNIFICANT TRANSACTIONS AND EVENTS FOR THE CURRENT PERIOD

The following significant transactions and events affected the financial performance and financial position of the Group for the period ended 30 September 2024:

Property, plant and equipment

During the period, the multi-storey car park building at our East Tāmaki, New Zealand campus has been substantially completed. Earthworks continue for the construction of a fifth building on our East Tāmaki site. Capital commitments at 30 September 2024 include \$4.1 million related to these projects. To date, spending on these projects totals \$103.1 million.

Borrowing facilities

The Group had total available committed external financing facilities of \$642.8 million as at 30 September 2024, of which approximately \$576.4 million was undrawn. As at 30 September 2024, the weighted average maturity of committed borrowing facilities was 2.2 years.

Share capital

During the period, the Group issued a total of 1,715,075 shares under the Dividend Reinvestment Plan (DRP) relating to the FY24 final dividend at an average price of \$28.9705 per share, totaling \$49.7 million. 433,988 shares were issued under employee share based payment arrangements.

3. OPERATING REVENUE AND SEGMENTAL INFORMATION

	Unaudited 2023 NZ\$M	Unaudited 2024 NZ\$M
For the six months ended 30 September		
Sales revenue	815.8	944.2
Foreign exchange gain (loss) on hedged sales	(12.1)	7.0
Total operating revenue	803.7	951.2
Revenue by product group		
Hospital products	487.5	591.4
Homecare products	314.4	359.4
	801.9	950.8
Distributed and other products	1.8	0.4
Total operating revenue	803.7	951.2
Revenue after hedging by geographical location of customer:		
North America	366.2	444.9
Europe	207.5	248.8
Asia Pacific	179.8	205.1
Other	50.2	52.4
Total operating revenue	803.7	951.2

4. OPERATING EXPENSES

	Unaudited 2023 NZ\$M	Unaudited 2024 NZ\$M
For the six months ended 30 September		
Profit before tax includes the following expenses:		
Depreciation – right-of-use assets	8.6	9.8
Depreciation and amortisation – other assets	45.8	57.6
Employee benefits expense	339.5	384.4

5. DERIVATIVE FINANCIAL INSTRUMENTS

Financial instruments are either carried at amortised cost, less any provision for impairment, or fair value. The carrying value of all financial assets and liabilities approximates fair value.

There have been no changes to the Group's hedging policy during the period. The Group enters into foreign currency option contracts or forward foreign currency contracts within policy parameters to manage the net risk associated with anticipated sales or costs. The Group generally applies hedge accounting to all derivative financial instruments.

All derivative financial instruments continue to be re-measured to their fair value. Derivative financial instruments continue to be classified as being within Level 2 of the fair value hierarchy and there were no changes in valuation techniques during the period.

Contractual amounts of derivative financial instruments were as follows:

	Audited 31 March 2024 NZ\$M	Unaudited 30 September 2024 NZ\$M
Foreign currency forward contracts and options		
Sale commitments forward exchange contracts	3,109.5	3,279.9
Purchase commitments forward exchange contracts	52.1	129.6
Foreign currency borrowing forward exchange contracts	64.2	67.1
Interest rate derivatives		
Interest rate swaps	2.5	2.5

Undiscounted foreign currency contractual amounts for outstanding hedges were as follows:

	Audited 31 March 2024 M	Unaudited 30 September 2024 M
Sale commitments		
United States dollars	US\$962.5	US\$948.0
European Union euros	€526.5	€599.0
Japanese yen	¥9,260.0	¥10,880.0
Purchase commitments		
Mexican pesos	MXN743.5	MXN1,710.0

6. COMMITMENTS

	Audited 31 March 2024 NZ\$M	Unaudited 30 September 2024 NZ\$M
Capital expenditure commitments contracted for but not recognised as at the reporting date:		
Within one year	21.6	18.1
Between one and two years	43.4	43.4
Between two and five years	15.0	15.0
	80.0	76.5

The commitments above include the commitment of \$58.0 million payable for the second New Zealand campus in Karaka (March 2024: \$58.0 million).

7. CONTINGENT LIABILITIES

Periodically, the Group is party to litigation including product liability and patent claims.

The Directors are unaware of the existence of any claim or contingencies that would have a material impact on the financial statements.

8. RELATED PARTY TRANSACTIONS

During the period, the Group has not entered into any material contracts involving related parties or Directors' interests. No amounts owed by related parties have been written off or forgiven during the period. Apart from Directors' fees, key executive remuneration and dividends paid by the Group to its Directors and key executives as shareholders of the company, there have been no related party transactions.

9. DIVIDENDS

On 28 May 2024, the Directors approved the payment of a fully imputed 2024 final dividend of \$137.2 million (23.5 cents per share) which was paid on 10 July 2024, gross of DRP. A supplementary dividend of 4.1471 cents per share was also paid to eligible non-resident shareholders.

Subsequent event – dividend declared

On 27 November 2024, the Directors approved the payment of a fully imputed 2025 interim dividend of \$108.4 million (18.5 cents per share) to be paid on 18 December 2024. A supplementary dividend of 3.2647 cents per share was also approved for eligible non-resident shareholders.

10. SIGNIFICANT EVENTS AFTER BALANCE DATE

Other than the dividend disclosed in Note 9, there are no other significant events after balance date.

Independent auditor's review report



To the shareholders of Fisher & Paykel Healthcare Corporation Limited

REPORT ON THE CONSOLIDATED FINANCIAL STATEMENTS

OUR CONCLUSION

We have reviewed the consolidated financial statements of Fisher & Paykel Healthcare Corporation Limited (the Company) and its subsidiaries (the Group), which comprise the consolidated balance sheet as at 30 September 2024, and the consolidated income statement, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the six months ended on that date, and notes to the consolidated financial statements, comprising material accounting policy information and other explanatory information.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements of the Group do not present fairly, in all material respects, the financial position of the Group as at 30 September 2024, and its financial performance and cash flows for the six months then ended, in accordance with International Accounting Standard 34 *Interim Financial Reporting* (IAS 34) and New Zealand Equivalent to International Accounting Standard 34 *Interim Financial Reporting* (NZ IAS 34).

BASIS FOR CONCLUSION

We conducted our review in accordance with the New Zealand Standard on Review Engagements 2410 (Revised) *Review of Financial Statements Performed by the Independent Auditor of the Entity* (NZ SRE 2410 (Revised)). Our responsibilities are further described in the *Auditor's responsibilities for the review of the consolidated financial statements* section of our report.

We are independent of the Group in accordance with the relevant ethical requirements in New Zealand relating to the audit of the annual financial statements, and we have fulfilled our other ethical responsibilities in accordance with these ethical requirements. In addition to our role as auditor, our firm carries out other services for the Group in the areas of providing market survey data relating to executive remuneration levels, regulatory tax compliance procedures in Mexico, and other assurance services in relation to constant currency disclosures and greenhouse gas emissions. The provision of these other services has not impaired our independence.

RESPONSIBILITIES OF DIRECTORS FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The Directors of the Company are responsible on behalf of the Company for the preparation and fair presentation of these consolidated financial statements in accordance with IAS 34 and NZ IAS 34 and for such internal control as the Directors determine is necessary to enable the preparation and fair presentation of the consolidated financial statements that are free from material misstatement, whether due to fraud or error.

AUDITOR'S RESPONSIBILITIES FOR THE REVIEW OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our responsibility is to express a conclusion on the consolidated financial statements based on our review. NZ SRE 2410 (Revised) requires us to conclude whether anything has come to our attention that causes us to believe that the consolidated financial statements, taken as a whole, are not prepared in all material respects, in accordance with IAS 34 and NZ IAS 34.

A review of consolidated financial statements in accordance with NZ SRE 2410 (Revised) is a limited assurance engagement. We perform procedures, primarily consisting of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with International Standards on Auditing and International Standards on Auditing (New Zealand) and consequently does not enable us to obtain assurance that we might identify in an audit. Accordingly, we do not express an audit opinion on these consolidated financial statements.

WHO WE REPORT TO

This report is made solely to the Company's shareholders, as a body. Our review work has been undertaken so that we might state those matters which we are required to state to them in our review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the shareholders, as a body, for our review procedures, for this report, or for the conclusion we have formed.

The engagement partner on the review resulting in this independent auditor's review report is Indumin Senaratne (Indy Sena).

For and on behalf of:

A handwritten signature in dark ink, appearing to read 'Indumin Senaratne'.

PricewaterhouseCoopers
Auckland

27 November 2024

Directory

DIRECTORS

Neville Mitchell	Board Chair, Non-Executive, Independent
Lewis Gradon	Managing Director and Chief Executive Officer
Mark Cross	Non-Executive, Independent
Michael Daniell	Non-Executive
Pip Greenwood	Non-Executive, Independent
Lisa McIntyre	Non-Executive, Independent
Graham McLean	Non-Executive, Independent
Cather Simpson	Non-Executive, Independent

EXECUTIVE MANAGEMENT TEAM

Lewis Gradon	Managing Director and Chief Executive Officer
Lyndal York	Chief Financial Officer
Andrew Somervell	Vice President – Products & Technology
Justin Callahan	Vice President – Sales & Marketing
Andy Niccol	Chief Operating Officer
Winston Fong	Vice President – Surgical Technologies
Brian Schultz	Vice President – Quality, Safety & Regulatory Affairs
Nicholas Fourie	Vice President – Information & Communication Technology
Marcus Driller	Vice President – Corporate
Nicola Talbot	Vice President – Human Resources
Jonti Rhodes	Vice President – Supply Chain, Facilities & Sustainability
Raelene Leonard	General Counsel & Company Secretary
Desh Edirisuriya	General Manager – New Zealand Operations

REGISTERED OFFICES

New Zealand:

Physical address:	15 Maurice Paykel Place, East Tāmaki, Auckland 2013, New Zealand
Telephone:	+64 9 574 0100
Postal address:	PO Box 14348, Panmure, Auckland 1741, New Zealand
Website:	www.fphcare.com
Email:	investor@fphcare.co.nz

Australia:

Physical address:	19-31 King Street, Nunawading, Melbourne, Victoria 3131, Australia
Telephone:	+61 3 9871 4900
Postal address:	PO Box 159, Mitcham, Victoria 3132, Australia

STOCK EXCHANGES

The company's ordinary shares are listed on the NZX Main Board and the ASX.

SHARE REGISTRAR

In New Zealand:

MUFG Pension & Market Services Limited

Physical address:	Level 30, PwC Commercial Bay, 15 Customs Street West, Auckland 1010, New Zealand
Postal address:	PO Box 91976, Auckland 1142, New Zealand
Facsimile:	+64 9 375 5990
Investor enquiries:	+64 9 375 5998
Website:	www.linkmarketservices.co.nz
Email:	enquiries@linkmarketservices.co.nz

In Australia:

MUFG Pension & Market Services Limited

Physical address:	Level 12, 680 George Street, Sydney, NSW 2000, Australia
Postal address:	Locked Bag A14, Sydney South, NSW 1235, Australia
Facsimile:	+61 2 9287 0303
Investor enquiries:	+61 2 8280 7111
Website:	www.linkmarketservices.com.au
Email:	registrars@linkmarketservices.com.au

— Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea.



Important notice

Disclaimer

The information in this presentation is for general purposes only and should be read in conjunction with Fisher & Paykel Healthcare Corporation Limited's (FPH) Interim Report 2025 and accompanying market releases. Nothing in this presentation should be construed as an invitation for subscription, purchase or recommendation of securities in FPH.

This presentation includes forward-looking statements about the financial condition, operations and performance of FPH and its subsidiaries. These statements are based on current expectations and assumptions regarding FPH's business and performance, the economy and other circumstances. As with any projection or forecast, the forward-looking statements in this presentation are inherently uncertain and susceptible to changes in circumstances. FPH's actual results may differ materially from those expressed or implied by those forward-looking statements.

Constant currency information included within this presentation is non-GAAP financial information, as defined by the NZ Financial Markets Authority, and has been provided to assist users of financial information to better understand and track the company's comparative financial performance without the impacts of spot foreign currency fluctuations and hedging results and has been prepared on a consistent basis each year. A reconciliation between reported results and constant currency results is available in the company's Interim Report 2025. The company's constant currency framework can be found on the company's website at www.fphcare.com/ccf.

Half year business highlights



RELEASED two new hardware platforms into the United States: the F&P 950™ System and Airvo™ 3



INITIATED sales of our new F&P Optiflow Duet™ in the United States



LAUNCHED our F&P Nova Micro™ nasal pillows mask for treating obstructive sleep apnea in New Zealand and Canada



COMMENCED sales of our F&P Solo™ nasal and pillows mask in the United States



BEGAN manufacturing at our new facility in Guangzhou, China



APPOINTED Mark Cross to the Board of Directors, and welcomed Neville Mitchell to the role of Board Chair

Key half year financial results


H1 FY25 (Six months to 30 September 2024)

	% of Revenue	NZ\$M	ΔPCP^	ΔCC*
Operating revenue	100%	951.2	18%	17%
Hospital operating revenue	62%	591.4	21%	21%
Homecare operating revenue	38%	359.4	14%	13%
Gross margin / Gross profit	62%	588.7	141 bps	198 bps
SG&A	27%	(260.5)	10%	10%
R&D	12%	(110.1)	14%	14%
Total operating expenses	39%	(370.6)	11%	11%
Operating profit	23%	218.1	43%	46%
Profit after tax	16%	153.2	43%	51%

30 Sep 2024 closing spot rates were USD 0.64, EUR 0.57 and MXN 12.54, resulting in a foreign exchange loss on balance sheet translations of NZ\$6.8M after tax for the period. Refer to slide 13 for more details.

Hospital product group

H1 FY25 HOSPITAL REVENUE COMPOSITION



■ Hardware ■ Consumables

H1 FY24 Hospital revenue composition
Hardware: 10% Consumables: 90%

HARDWARE



F&P 950 System



F&P 850 System



F&P Airvo 3



F&P Airvo 2



F&P HumiGard

CONSUMABLES



Invasive ventilation



Noninvasive ventilation



Optiflow™ nasal high flow



Optiflow™ anesthesia



Surgical



Hospital product group

H1 FY25

HOSPITAL OPERATING REVENUE

\$591.4M


NZ\$ ↑ 21%

CONSTANT CURRENCY ↑ 21%

NEW APPLICATIONS
CONSUMABLES
REVENUE*

NZ\$ ↑ 25%


CONSTANT CURRENCY ↑ 24%



- Sales were supported by ongoing change in clinical practice, a good response to new product introductions, and indications of a relatively strong hospital census during the period
- New applications consumables* revenue made up 73% of H1 FY25 Hospital consumables revenue, up from 71% in H1 FY24
- Hospital hardware revenue was up 25% on H1 FY24 in constant currency

Homecare product group

H1 FY25 HOMECARE REVENUE COMPOSITION



■ Hardware ■ Consumables

HARDWARE



CONSUMABLES



H1 FY24 Homecare revenue composition
Hardware: 13% Consumables: 87%

Homecare product group

H1 FY25

HOME CARE OPERATING REVENUE

\$359.4M


NZ\$ ↑ 14%

CONSTANT CURRENCY ↑ 13%


OSA MASKS
REVENUE

NZ\$ ↑ 16%

CONSTANT CURRENCY ↑ 14%




F&P Solo



- F&P Evora™ Full continued to make a strong contribution to revenue
- Revolutionary F&P Solo™ mask launched in the United States in April 2024
- F&P Nova Micro™ was launched in NZ and Canada early in H1 FY25, with a US launch occurring in November 2024


Gross margin



- Gross margin for the half year:
 - increased by 141 bps to 61.9%
 - increased by 198 bps in constant currency
- This margin improvement reflects the ongoing progress of our continuous improvement initiatives and overhead efficiency.

Operating margin

OPERATING (EBIT) MARGIN



..... Long Term Operating Margin target

Operating expenses

- \$370.6M, +11% (+11% CC)
- Operating margin increased by 394 bps (+420 bps CC) to 22.9%

Research & Development expenses

- \$110.1M, +14% (+14% CC)
- Estimate ~60% of R&D spend eligible for tax credit for the full year
- \$9M recognised for the tax credit in first half

Selling, General & Administrative expenses

- \$260.5M, +10% (+10% CC)


Cash flow and balance sheet

	H1 FY24 NZ\$M	H1 FY25 NZ\$M
Operating cash flow	156.5	233.0
Capital expenditure (including purchases of intangible assets)	(275.5)	(55.1)
Lease liability payments	(8.5)	(8.5)
Free cash flow	(127.5)	169.4
	31 Mar 2024 NZ\$M	30 Sep 2024 NZ\$M
Net cash / (debt)	(32.2)	50.0
Total assets	2,281.7	2,435.4
Total equity	1,759.1	1,929.8
Gearing (net debt / net debt + equity)*	1.8%	-2.9%
Undrawn committed debt facilities	544.3	576.4

* Calculated using net interest-bearing debt (debt less cash and cash equivalents) to net interest-bearing debt and equity (less hedge reserve).

Dividend

- Increased interim dividend by 3% compared with the FY24 interim dividend
 - 18.5 cps + 7.19 cps imputation credit for NZ residents (gross dividend of NZ 25.69 cps)
 - Fully imputed
 - 3.26 cps non-resident supplementary dividend
- Dividend reinvestment plan (DRP) suspended



Foreign exchange effects

	H1 FY24 NZ\$M	H1 FY25 NZ\$M	Change NZ\$M
Reconciliation of Constant Currency to Reported Revenue			
Revenue (constant currency)	783.8	919.5	135.7
Spot exchange rate effect	28.1	24.7	(3.4)
Foreign exchange hedging result	(12.1)	7.0	19.1
Balance sheet revaluation*	3.9	-	(3.9)
Total impact of foreign exchange	19.9	31.7	11.8
Revenue (as reported)	803.7	951.2	147.5
Reconciliation of Constant Currency to Reported Profit After Tax			
Profit after tax (constant currency)	96.1	144.7	48.6
Spot exchange rate effect	14.8	6.0	(8.8)
Foreign exchange hedging result	(2.0)	9.3	11.3
Balance sheet revaluation*	(1.6)	(6.8)	(5.2)
Total impact of foreign exchange	11.2	8.5	(2.7)
Profit after tax (as reported)	107.3	153.2	45.9

The significant exchange rates used in the constant currency analysis, being the budget exchange rates for the year ended 31 March 2025, are USD 0.64, EUR 0.57 and MXN 11.0.

*From 1 April 2024, all foreign exchange gains and losses from balance sheet revaluations are presented in net financing expenses.

Outlook FY25

Operating revenue and net profit after tax

At 31 October exchange rates*, the company continues to guide to the following:

- full-year operating revenue in the range of approximately \$1.9 billion to \$2.0 billion
- full-year net profit after tax in the range of approximately \$320 million to \$370 million.

Hospital

We expect similar contributions from change in clinical practice and new product introductions. Guidance also accommodates a broad range of Northern Hemisphere seasonal hospitalisation scenarios, ranging from relatively low to approximately moderate. This variable impact typically occurs later in our second half.

Homecare

We expect our three new mask models to continue to drive similar results for the remainder of the financial year.

*At 31 Oct 2024 exchange rates of NZD:USD 0.59, NZD:EUR 0.55, NZD:MXN 12.05.

「Key Financials

Hedging cover

- 49% of operating revenue in US\$ (H1 FY24: 49%) and 19% in € (H1 FY24: 19%).

Year to 31 March

Hedging position for our main exposures (as at 13 November 2024)	FY25	FY26	FY27	FY28	FY29	FY30- FY35*
USD % cover of estimated exposure	94%	80%	68%	50%	20%	1%
USD average rate of cover	0.619	0.608	0.599	0.588	0.566	0.523
EUR % cover of estimated exposure	95%	80%	68%	53%	43%	11%
EUR average rate of cover	0.536	0.535	0.529	0.527	0.510	0.474
MXN % cover of estimated exposure	86%	58%	38%	15%	6%	0%
MXN average rate of cover	12.67	12.49	12.92	14.07	14.64	15.06


Hedging cover percentages have been rounded to the nearest 5%

* 2030 – 2035 shows average % cover of expected exposure and rate of cover for the five-year period.

Revenue and expenses by currency


H1 FY25 (for the six months ended 30 September 2024)

REVENUE BY CURRENCY




■ NZD ■ USD ■ EUR ■ MXN ■ Other

COST OF SALES BY CURRENCY



■ NZD ■ USD ■ EUR ■ MXN ■ Other

OPERATING EXPENSES BY CURRENCY



■ NZD ■ USD ■ EUR ■ MXN ■ Other

Overview



Fisher & Paykel Healthcare at a glance

Global leader in respiratory humidification devices

- Medical device manufacturer with leading positions in respiratory care and obstructive sleep apnea
- >50 years' experience in changing clinical practice to solutions that provide better clinical outcomes and improve effectiveness of care
- Estimated NZ\$25+ billion and growing market opportunity driven by demographics
- Significant organic long-term growth opportunities in acute and chronic respiratory care, OSA and surgery
- Large proportion (89%) of revenue from recurring items, consumables and accessories
- High level of innovation and investment in R&D with strong product pipeline
- High barriers to entry

Global presence

Our people
are located in
54 countries



3,544
in New Zealand

2,675
in North America,
including Mexico

389
in Europe

533
in the rest
of the world

Strong financial performance

- Continued target, and history of, doubling our revenue (in constant currency terms) every 5 to 6 years
- Targeting gross margin of 65% and operating margin of 30%
- Growth company with a strong history of increasing dividend payments

~NZ\$25+ billion and growing market opportunity

Total addressable market estimates

HOSPITAL

~150+ million patients

Invasive Ventilation



Noninvasive Ventilation



Hospital Respiratory Support



Anesthesia



Infant Care



Surgical



NEW APPLICATIONS

Applications outside of invasive ventilation



HEMOCARE

~100+ million patients

Home Respiratory Support




Obstructive Sleep Apnea








Our aspiration



OUR ASPIRATION:
Sustainably
DOUBLING
our constant
currency revenue
every 5-6 years.

21 The image above is an illustration of the company's long-term growth aspirations. It is not a graph and should not be interpreted as being indicative of levels of revenue or profitability in the short term.

Consistent growth strategy



F&P product fundamentals



What are we here to do?

A drive to not only improve, but transform,
clinical practice.

Provide products with protected value
differentiation.

Get our products, including the evidence,
knowledge and supporting tools, into the hands of
the customer


**A deep understanding of the problem and knowing what we are trying to
achieve, leads to valued, innovative solutions**

A patient-focused approach

A drive to deliver and improve

Long-term thinking

High level of innovation and investment in R&D




- R&D represents 12% of operating revenue*: NZ\$110.1M in 1H FY25
- Product pipeline includes:
 - Humidifier controllers
 - Masks
 - Respiratory consumables
 - Flow generators
 - Compliance monitoring solutions
- 632 US patents, 573 US pending, 3,103 Rest of World patents, 1,886 Rest of World pending[†]



Growing patent portfolio



FISHER & PAYKEL HEALTHCARE US PATENT PORTFOLIO (2008 – 2024)



Average remaining life of FPH patent portfolio (all countries): 10.7 years*

Changing clinical practice



- Using clinical evidence to drive change
- Multi-layered with multiple stakeholders
- Building confidence with usage in line with the evidence, demonstrating value
- Products in each care area builds familiarity and confidence
- Customer experience builds trust and confidence
- Online F&P Education Hub available in 21 languages and currently accessed by professionals in more than 90 countries



Strong global presence



- **Direct/offices**

- Hospitals, homecare dealers
- Sales/support offices in North America, Europe, Asia, South America, Middle East and Australasia, 21 distribution centres
- ~1,400 employees in 54 countries
- Ongoing international expansion

- **Distributors**


- 180+ distributors worldwide

- **Original equipment manufacturers**

- Supply most leading ventilator manufacturers

- **Sell in more than 120 countries**

Revenue by Region
Six months to 30 September 2024



Manufacturing and operations



New Zealand

- Four buildings: 110,000 m² / 1,180,000 ft²
- Co-location of R&D and manufacturing
- Continued development of East Tāmaki campus

Tijuana, Mexico

- Three buildings: 63,000 m² / 690,000 ft²

Guangzhou, China

- First shipment of product from our new manufacturing site in July



「 Hospital




Invasive ventilation



Invasive ventilation refers to respiratory support delivered directly to a patient's lower airways via an endotracheal (ET) or tracheostomy tube.

- Normal airway humidification is bypassed or compromised during ventilation
- Mucociliary transport system operates less effectively
- Need to deliver gas at physiologically normal levels
 - 37°C body core temperature
 - 44mg/L 100% saturated



New applications consumables

New applications consist of:



Noninvasive
ventilation



Optiflow™
nasal high flow




Optiflow™
anesthesia



Surgical

CONSTANT CURRENCY REVENUE GROWTH RATE
IN NEW APPLICATIONS CONSUMABLES*



* Adjusted to exclude impact of US distribution transition in FY16 and FY17

Noninvasive ventilation




Noninvasive ventilation involves the delivery of oxygen (ventilation support) via a face mask and without the need for endotracheal intubation.

Reasons for requiring noninvasive ventilation:

- Acute and chronic respiratory failure, chronic obstructive pulmonary disease, cystic fibrosis, Duchenne muscular dystrophy, neuromuscular disease, obesity hypoventilation syndrome, respiratory distress syndrome (typically due to preterm birth), restrictive thoracic disorders.
- The ERS ATS and AARC guidelines recommend the use of humidification during NIV.

Humidified noninvasive ventilation



A Flow driver



NIV capable
mechanical ventilator

B Humidifier



F&P 950
Mask
mode

F&P 850
Mask
mode

C Tube and chamber kit

F&P AirSpiral

D Interface

F&P Nivairo
F&P Visairo

Our NIV masks and their unique features



F&P Nivairo



RollFit™ auto-adjusting seal



Patented TubeFit™ technology



Bridge-free™ NIV

F&P Visairo



Optiflow nasal high flow therapy




Optiflow nasal high flow therapy provides respiratory support to patients by delivering heated, humidified air and oxygen at flow rates up to 70 L/min via an Optiflow nasal cannula and a system such as the Airvo 2, Airvo 3, F&P 850 or 950.


Patient groups who may benefit from Optiflow:

- Acute respiratory failure, asthma, atelectasis, bronchiectasis, bronchiolitis, bronchitis, burns, carbon monoxide poisoning, COPD, chest trauma, emphysema, infant respiratory distress, palliative care, pneumonia, pulmonary embolism, respiratory compromise, viral pneumonia

Airvo Optiflow NHF Therapy system



Vent-driven Optiflow NHF Therapy system



Optiflow - displacing conventional oxygen therapy

CONVENTIONAL OXYGEN THERAPY



Low flow nasal prongs Simple face mask Rebreather mask

NON-INVASIVE VENTILATION



F&P **Optiflow**
Nasal high flow therapy









~6+million

Estimated patients were treated with our Optiflow high flow therapy during the 2024 financial year

Clinical practice guidelines: NHF therapy




	SUPPORTING CLINICAL PRACTICE GUIDELINES	EMERGENCY DEPARTMENT	ICU/HDU	RESPIRATORY	GENERAL
 Primary support MEDICAL	ESICM, ERS, SSC, AARC, ACP, TSANZ, WHO	✓	✓	✓	
 Primary support POST-OPERATIVE	ESICM, ERS		✓		
 Pre-escalation support/ Peri-intubation	ESICM	✓	✓		
 Post-extubation/ De-escalation support	ESICM, ERS, AARC, ACP		✓		
 Complementary support (NIV-rested/proning)	ERS	✓	✓	✓	✓
 Prophylactic support (Require oxygen/avoid escalation)	AARC	✓	✓	✓	✓

Clinical practice guidelines: ESICM¹, ERS², SSC³, AARC⁴, ACP⁵, TSANZ⁶, WHO⁷

A growing body of clinical evidence



NASAL HIGH FLOW CLINICAL PAPERS PUBLISHED ANNUALLY




- The publication of 638 clinical papers on NHF during the 2023 calendar year signifies ongoing clinical interest in the therapy

Source: PubMed. Includes adult and paediatric/neonatal studies.

Optiflow in Anesthesia



The F&P Optiflow THRIVE™ system enables users to deliver THRIVE™ transnasal humidified rapid-insufflation ventilatory exchange and nasal high flow (NHF) therapy, which has been shown to optimize oxygenation during general anesthesia and procedural sedation.



In Procedural Sedation

- Optimize oxygenation
- Reduce risk of desaturation
- Reduce the incidence of airway related interventions



In General Anesthesia

- Effective preoxygenation
- Reduce risk of desaturation
- Extend safe apnea time



Fisher & Paykel
HEALTHCARE

Surgical humidification



Surgical humidification is the delivery of warm, humidified CO₂ in laparoscopic and open surgery.

- Current standard of care is dry CO₂ gas to the surgical site
- Causes evaporation and cooling
- Surgical humidification reduces the incidence of peri-operative hypothermia^{8,9} and improves core body temperature at the end of surgery in both laparoscopic¹⁰ and open surgery⁹.



「Homecare



Obstructive sleep apnea



Obstructive sleep apnea (OSA) is characterized by episodes of a complete (apnea) or partial collapse (hypopnea) of the upper airway with an associated decrease in oxygen saturation or arousal from sleep.

- OSA is an underdiagnosed medical condition, with multiple negative outcomes to patients' health
- It can greatly impair quality of sleep, leading to fatigue; also associated with hypertension, stroke and heart attack
- Estimate >100 million people affected in developed countries
- Most common treatment is CPAP (Continuous Positive Airway Pressure)
 - Key issue with CPAP is compliance
 - The mask is the one component of the CPAP therapy system that the patient interacts most intimately, so choosing the right mask is critical.



Mask matters most




- Masks are key to compliance
- Unique, patented designs
- Released our new F&P Solo™ mask into the United States in April, while Nova Micro™ was launched in New Zealand and Canada during the half



F&P Evora Nasal



F&P Evora Full



F&P Solo



F&P Nova Micro

Home respiratory support



The F&P myAirvo™ system delivers humidified high flow therapy to chronic respiratory patients at home and in long-term care facilities.

- Chronic obstructive pulmonary disease (COPD) is a lung disease which is commonly associated with smoking
- Chronic respiratory disease, primarily COPD, is the third leading cause of death in the world¹¹
- 4-10% COPD prevalence worldwide¹² (~400 million people)
- Humidified high flow therapy delivers a mix of warm, moist air and supplementary oxygen (when required) to help COPD patients¹³:
 - Ease respiratory disease symptoms
 - Reduce escalation of care
 - Improve quality of life



The background image shows a modern, white, multi-story building with large glass windows and a facade of vertical slats. In the foreground, there is a landscaped area with a pond, a wooden walkway, and various plants, including tall grasses and dark-leafed shrubs. The sky is blue with white clouds.

Operating Sustainably

Environmental, Social & Governance

Our People

The Board approved a discretionary profit-sharing payment of \$6 million in the first half for those who have worked for the company for a qualifying period.

Community and Volunteer Groups

We are proud of the community groups supported through the Fisher & Paykel Healthcare Foundation. During the 2024 financial year, the Foundation provided \$1.125M in grants and donations to 15 community organisations. Refer to our 2024 Annual Report for more details.

Sustainable Procurement

FY24 Highlights:

- Hosted our inaugural Supplier Sustainability Conference in New Zealand
- Rolled out our Sustainable Procurement Framework in Mexico
- Commenced risk mapping of Tier 2 suppliers

Key Environmental Metrics	FY22	FY23	FY24
Scope 1 emissions (tonnes CO ₂ e)	1,777	2,287	2,123
Scope 2 emissions (tonnes CO ₂ e) – location-based	13,894	14,529	14,293
Scope 2 emissions (tonnes CO ₂ e) – market-based	10,344	11,105	12,253
Scope 1 & 2 emissions subtotal (tonnes CO ₂ e) – using location-based Scope 2	15,671	16,816	16,416
Scope 1 & 2 emissions subtotal (tonnes CO ₂ e) – using market-based Scope 2	12,121	13,392	14,376
Scope 3 emissions (tonnes CO ₂ e)	457,112	328,313	302,479
Total emissions (tonnes CO₂e) - using location-based Scope 2	472,783	345,129	318,895
Total emissions (tonnes CO₂e) - using market-based Scope 2	469,233	341,705	316,855
Water usage (cubic metres)	184,171	133,517	136,923
Landfill waste diverted (cubic metres)	2,035	1,727	1,348
NZ recycling efficiency (percentage of waste diverted from landfill)	68%	62%	59%
Global recycling efficiency (percentage of waste diverted from landfill)	52%	54%	53%

Sustainability disclosures and indices

We participate annually in a suite of well-respected sustainability disclosure programmes and are included in the Dow Jones Sustainability Index and the FTSE4Good index.

Member of

Dow Jones Sustainability Indices

Powered by the S&P Global CSA




FTSE4Good




Ownership structure and listings

- Listed on NZX and ASX (NZX.FPH, ASX.FPH)

Shareholding structure as at
30 September 2024



Geographical ownership as at
30 September 2024



References

1. Rochwerf, Bram et al. "The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline." *Intensive care medicine* vol. 46,12 (2020): 2226-2237. doi:10.1007/s00134-020-06312-y
2. Oczkowski, Simon, et al. "ERS Clinical Practice Guidelines: High-flow Nasal Cannula in Acute Respiratory Failure." *European Respiratory Journal*, vol. 59, no. 4, European Respiratory Society (ERS), Oct. 2021, p. 2101574. Crossref, <https://doi.org/10.1183/13993003.01574-2021>.
3. Evans, Laura, et al. "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021." *Critical Care Medicine*, vol. 49, no. 11, Ovid Technologies (Wolters Kluwer Health), Oct. 2021, pp. e1063–143. Crossref, <https://doi.org/10.1097/ccm.0000000000005337>.
4. Piraino, Thomas, et al. "AARC Clinical Practice Guideline: Management of Adult Patients With Oxygen in the Acute Care Setting." *Respiratory Care*, vol. 67, no. 1, Daedalus Enterprises, Nov. 2021, pp. 115–28. Crossref, <https://doi.org/10.4187/respcare.09294>.
5. Qaseem, Amir, et al. "Appropriate Use of High-Flow Nasal Oxygen in Hospitalized Patients for Initial or Postextubation Management of Acute Respiratory Failure: A Clinical Guideline From the American College of Physicians." *Annals of Internal Medicine*, vol. 174, no. 7, American College of Physicians, July 2021, pp. 977–84. Crossref, <https://doi.org/10.7326/m20-7533>.
6. Barnett, Adrian, et al. "Thoracic Society of Australia and New Zealand Position Statement on Acute Oxygen Use in Adults: 'Swimming Between the Flags.'" *Respirology*, vol. 27, no. 4, Wiley, Feb. 2022, pp. 262–76. Crossref, <https://doi.org/10.1111/resp.14218>.
7. Clinical management of COVID-19: Living guideline, 23 June 2022. Geneva: World Health Organization; 2022 (WHO/2019-nCoV/Clinical/2022.1). Licence: CC BY-NC-SA 3.0 IGO.
8. Mason, S. E., Kinross, J. M., Reynecke, D., Hendricks, J. & Arulampalam, T. H. (2015). Cost-effectiveness of warm humidified CO2 to reduce surgical site infections in laparoscopic colorectal surgery: a cohort study. *Gut*, 64, A556. <http://dx.doi.org/10.1136/gutjnl-2015-309861.1220>.
9. Frey, J. M., Janson, M., Svanfeldt, M., Svenarud, P. & van der Linden, J. A. (2012). Local insufflation of warm, humidified CO2 increases open wound and core temperature during open colon surgery: a randomized clinical trial. *Anesthesia Analgesia*, 115(5), 1204–1211. <https://doi:10.1213/ANE.0b013e31826ac49f>.
10. Matsuzaki, S., Vernis, L., Bonnin, M., Houille, C., Fournet-Fayard, A., Rosano, G., Lafaye, A. L., Chartier, C., Barriere, A., Storme, B., Bazin, J-E., Canis, M., Botchorishvili, R. (2017). Effects of low intraperitoneal pressure and a warmed, humidified carbon dioxide gas in laparoscopic surgery: a randomized clinical trial. *Scientific Reports*, 7(1), 11287. <https://doi.org/10.1038/s41598-017-10769-1>.
11. World Health Organization (2018) The top 10 causes of death, Available at: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death> (Accessed: 24 May 2018)
12. Nicole M Kosacz, Antonello Punturieri et al. Chronic Obstructive Pulmonary Disease Among Adults -United States 2011. US Centers for Disease Control and Prevention, 2012.
13. Storgaard LH, et al. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. *Int J Chron Obstruct Pulmon Dis* 2018;13:1195-1205.

28 November 2024
Results Announcement

Results for announcement to the market		
Name of issuer	Fisher & Paykel Healthcare Corporation Limited	
Reporting Period	6 months to 30 September 2024	
Previous Reporting Period	6 months to 30 September 2023	
Currency	NZD	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$951,200	+18%
Total Revenue	\$951,200	+18%
Net profit/(loss) from continuing operations	\$153,200	+43%
Total net profit/(loss)	\$153,200	+43%
Interim Dividend		
Amount per Quoted Equity Security	0.18500000 \$/share	
Imputed amount per Quoted Equity Security	0.07194444 \$/share	
Record Date	06 December 2024	
Dividend Payment Date	18 December 2024	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	As at 30 September 2024: 3.05009576 \$/share	As at 30 September 2023: 2.68258788 \$/share
A brief explanation of any of the figures above necessary to enable the figures to be understood	Not applicable	
Authority for this announcement		
Name of person authorised to make this announcement	Raelene Leonard	
Contact person for this announcement	Raelene Leonard	
Contact phone number	+64 9 610 4803	
Contact email address	companysecretary@fphcare.co.nz	
Date of release through MAP	28 November 2024	

Reviewed financial statements accompany this announcement.

28 November 2024
Distribution Notice

Section 1: Issuer information				
Name of issuer	Fisher & Paykel Healthcare Corporation Limited			
Financial product name/description	Interim Dividend			
NZX ticker code	FPH			
ISIN	NZFAPE0001S2			
Type of distribution	Full Year		Quarterly	
	Half Year	X	Special	
	DRP applies			
Record date	06 December 2024			
Ex-Date	05 December 2024			
Payment date	18 December 2024			
Total monies associated with the distribution	\$108,433,108 based on shares on issue at 27 November 2024 for cash distribution			
Source of distribution	Retained earnings			
Currency	NZD			
Section 2: Distribution amounts per financial product				
Gross distribution	0.25694444 \$/share			
Gross taxable amount	0.25694444 \$/share			
Total cash distribution	0.18500000 \$/share			
Excluded amount	N/A			
Supplementary distribution amount	0.03264706 \$/share			
Section 3: Imputation credits and Resident Withholding Tax				
Is the distribution imputed	Fully imputed			
If fully or partially imputed, please state imputation rate as % applied	100%			
Imputation tax credits per financial product	0.07194444 \$/share			
Resident Withholding Tax per financial product	0.01284722 \$/share			
Section 4: Distribution re-investment plan (if applicable)				
DRP % discount (if any)				
Start date and end date for determining market price for DRP				
Date strike price to be announced (if not available at this time)				
Specify source of financial products to be issued under DRP programme (new issue or to be bought on market)				

DRP strike price per financial product	
Last date to submit a participation notice for this distribution in accordance with DRP participation terms	
Section 5: Authority for this announcement	
Name of person authorised to make this announcement	Raelene Leonard
Contact person for this announcement	Raelene Leonard
Contact phone number	+64 9 610 4803
Contact email address	companysecretary@fphcare.co.nz
Date of release through MAP	28 November 2024